Peter Halling – CEO & President, ALK
The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines…
The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines…
Nicolas Dufourt leads ALK France as General Manager, drawing on nearly two decades of tenure with the Danish allergy immunotherapy specialist. Under his stewardship, the French affiliate, comprising approximately 400…
Peter Halling, CEO of ALK, leads the century-old allergy immunotherapy innovator through a transformative phase focused on expanding patient access and innovation globally. In this interview, Halling discusses ALK’s Allergy+…
With a mandate spanning pharmaceuticals, medical devices, and clinical research, the Danish Medicines Agency plays a central role in shaping both national health policy and European regulatory alignment. Under the…
Coming to ALK China from an extensive and varied career, Xian Ji has helped build a new strategy for the allergy specialist’s local affiliate, which has led to quintupled business…
Trad Alkhelaiwi lays out the scale of Johnson & Johnson’s transformation in Saudi Arabia, particularly the transition to a direct model in the medtech space, reflecting the company’s long-term commitment…
Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including…
Trad Alkhelaiwi, country director for Amgen in Saudi Arabia, discusses the intricacies of the Saudi healthcare transformation including the push for a value-based healthcare system that adopts best practices from…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Jorge Alderete, president of ALK Americas, outlines the Danish mid-cap’s strategy in the challenging US market, including innovative market access initiatives, and how future models of patient-doctor interaction and medical…
Schalk Opperman, general manager of Merck Romania explains the key factors behind successful product launches in what is an unpredictable market. He shares his insights on Merck’s impressive growth in…
Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview…
Branislav Kotlarik, Ferring’s general manager for the Balkans – whose remit includes Hungary, Romania and Bulgaria as well as all of ex-Yugoslavia – gives his insights into managing such a…
Milica Glisic, with over 15 years of experience in the pharma business and ten years at Wörwag Pharma, discusses the strong workforce in the Balkans, Wörwag Pharma’s mission in the…
Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends…
Ludmila Bezpalko, CEO of Borshchahivskiy Chemical Pharmaceutical Plant (BCPP), a top 10 domestic pharmaceutical company in Ukraine, documents the development strategy she has been following over the past two decades…
Recently arrived from Germany, ALK’s new general manager for Switzerland highlights some of the unique features of the Swiss allergology field, and some of the opportunities for ALK to positively…
The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical presence in the…
Sean Connor, General Manager Benelux and UK/ROI for ALK, details the company’s strategy both in terms of products and therapeutic areas and provides us with his assessment of Netherlands regulatory…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
Rikus Wolbers, Director at Novio Tech Campus, a key international incubator for R&D and manufacturing companies who are active at the interface of life sciences and high tech, and John…
Graham Skarnvad arrived to Spain as country manager of ALK’s Spanish affiliate at the end of 2009, right when the crisis was in full swing. Later on he took the…
Can you please tell our readers, what were some of ALK’s highlights in 2012? We had several important milestones in 2012. We advanced our research and development pipeline and made…
After establishing the operations of ChemPartner in 2009, can you tell our readers why Denmark? ChemPartner is a leading contract research laboratory within drug discovery. When ChemPartner was openly reviewing…
Mr. Cooke, you joined Alkermes after the company acquired the Elan Drug Technologies (EDT) unit in 2011—a unit you headed for four years. Can you please begin by introducing yourself…
Can you please introduce us to Dalkia? Pat Gilroy: Dalkia is a multinational company that operates in over 40 countries throughout the world and turns over 8Bn EUR annually. We…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines…
Nicolas Dufourt leads ALK France as General Manager, drawing on nearly two decades of tenure with the Danish allergy immunotherapy specialist. Under his stewardship, the French affiliate, comprising approximately 400…
Making Life Sciences Strategic The super-sized contribution of the life sciences sector to Denmark’s national economy can hardly be overstated. With over 100,000 professionals currently engaged in biotech and pharmaceuticals…
While Big Pharma giants chase blockbuster drugs across multiple therapeutic areas, three Danish mid-cap companies are pursuing a different path to survival. Facing mounting pressures and global competition, ALK, LEO…
Peter Halling, CEO of ALK, leads the century-old allergy immunotherapy innovator through a transformative phase focused on expanding patient access and innovation globally. In this interview, Halling discusses ALK’s Allergy+…
Coming to ALK China from an extensive and varied career, Xian Ji has helped build a new strategy for the allergy specialist’s local affiliate, which has led to quintupled business…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59,…
With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new…
The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related…
See our Cookie Privacy Policy Here
